Urinary Aquaporin 2 Excretion After NSAID in Fasting Healthy Human

This study has been completed.
Sponsor:
Information provided by:
Regional Hospital Holstebro
ClinicalTrials.gov Identifier:
NCT00281762
First received: January 23, 2006
Last updated: May 6, 2008
Last verified: May 2008
  Purpose

We wanted to test the hypothesis that prostaglandin inhibition reduces the down regulation of u-AQP-2 induced by fasting


Condition Intervention Phase
Healthy
Drug: NSAID
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Official Title: Urinary Aquaporin 2 Excretion After NSAID in Fasting Healthy Human

Further study details as provided by Regional Hospital Holstebro:

Primary Outcome Measures:
  • FeNa
  • U-AQP-2

Estimated Enrollment: 20
Study Completion Date: January 2007
Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • (1) Genders; both mal and female
  • (2) Age; 18- 65 years old
  • (3) BMI; below 30
  • (4) Females had to bee in oral contraceptive treatment

Exclusion Criteria:

  • (1) Clinical signs or history of disease in the heart, lungs, kidneys or endocrine organs
  • (2) Abnormal laboratory test (blood haemoglobin, white cell count, platelets, plasma sodium, plasma potassium, plasma creatinine, plasma albumin, plasma bilirubin, plasma alanine aminotransferase, plasma cholesterol and blood glucose)
  • (3) Albuminuria or glucosuria
  • (4) Cancer
  • (5) Arterial hypertension
  • (6) Alcohol abuse
  • (7) Use of tobacco
  • (8) Medical treatment, except oral contraceptives
  • (9) Pregnancy or breast feeding
  • (10) Medicine abuse
  • (11) Donation of blood less than 1 month before the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00281762

Locations
Denmark
Department of Medicine, Holstebro Hospital
Holstebro, Denmark
Sponsors and Collaborators
Regional Hospital Holstebro
Investigators
Study Chair: Erling B Pedersen, Professor Regional Hospital Holstebro
Principal Investigator: Thomas G Knudsen, MD Regional Hospital Holstebro
  More Information

No publications provided by Regional Hospital Holstebro

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00281762     History of Changes
Other Study ID Numbers: MED.RES.HOS.2005.01.TGK
Study First Received: January 23, 2006
Last Updated: May 6, 2008
Health Authority: Denmark: Ethics Committee

Keywords provided by Regional Hospital Holstebro:
AQP-2
NSAID
Urinary concentrating ability

Additional relevant MeSH terms:
Anti-Inflammatory Agents, Non-Steroidal
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Antirheumatic Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 22, 2014